TFRC and neoplasm: In that system, two monoclonal antibody ligands on liposomes were used for delivering shRNA into specific tumour cells, one against the transferrin receptor that exists on the BBB, and the other against the insulin receptor that was used for subsequent targeting of the liposomes to the brain tumour cells (Mathupala et al, 2006).